Kathryn E. Packman

6.8k citations

62 papers · 5.5k · 2 hit papers · h-index 34

Impact in

Oncology top 1%
- Cancer-related Molecular Pathways
Molecular Biology top 5%
- Melanoma and MAPK Pathways
- Chemical Synthesis and Analysis
- Protein Degradation and Inhibitors

Papers in

Oncology 25
- Cancer-related Molecular Pathways 13
- Cancer Immunotherapy and Biomarkers 4
Hematology 8
- Acute Myeloid Leukemia Research 5

Co-authors: Brian Higgins (18 shared papers)Christian Tovar (12 shared papers)Kenneth Daniel Kolinsky (17 shared papers)David C. Heimbrook (16 shared papers)Zoran Filipovic (6 shared papers)Lyubomir T. Vassilev (8 shared papers)Binh Thanh Vu (4 shared papers)Bradford J. Graves (8 shared papers)
Journals: Molecular Cancer Therapeutics (10 papers)Cancer Research (8 papers)Blood (5 papers)Journal of Medicinal Chemistry (5 papers)ACS Medicinal Chemistry Letters (4 papers)
Partner nations: United States Switzerland Belgium

In The Last Decade

Kathryn E. Packman

59 papers receiving 5.4k citations

Kathryn E. Packman's Hit Papers

align trajectories log scale

Stapled α−helical peptide drug development: A potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy 2013 · 579 citations

What are hit papers?

Paper score: A paper's citations measured against the top-1% bar of its own field and year: the square root of citations ÷ bar, so 1 means right at the bar and 2 means four times its citations. The bar blends the citation counts that enter the top 1% of the paper's subfields in its year (weighted 89.5%), of those subfields over all years (0.5%) and of its year across all fields (10%); a subfield and year with fewer than 400 papers takes its year's bar. Papers from 2026 are not scored yet: in an unfinished year, when a paper appeared matters more than how it is cited.

Hit paper: A paper cited at least 1.5× the top-1% bar of its field and year: a paper score of at least √1.5.

2013 Proceedings of the National Academy of Sciences
2013 Journal of Medicinal Chemistry

Peers

Countries citing papers authored by Kathryn E. Packman

Since Specialization

Citations

This map shows the geographic impact of Kathryn E. Packman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kathryn E. Packman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kathryn E. Packman more than expected).

Fields of papers citing papers by Kathryn E. Packman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kathryn E. Packman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kathryn E. Packman. The network helps show where Kathryn E. Packman may publish in the future.

Co-authors

The 25 scholars most cited alongside Kathryn E. Packman, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Kathryn E. Packman Line = papers co-authored together Kathryn E. Packman links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 62 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: Implications for therapy Proceedings of the National Academy of Sciences ·Christian Tovar, James Rosinski, Zoran Filipovic, Brian Higgins, Kenneth Daniel Kolinsky, Holly Hilton, Xiaolan Zhao, Binh Thanh Vu	2006	585
2	Stapled α−helical peptide drug development: A potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy Proceedings of the National Academy of Sciences ·Yong Seok Chang, Bradford J. Graves, Vincent Guerlavais, Christian Tovar, Kathryn E. Packman, Kwong-Him To, Karen A. Olson, Kamala P. Kesavan Hit paper breakdown →	2013	579
3	Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development Journal of Medicinal Chemistry ·Qingjie Ding, Zhuming Zhang, Jinjun Liu, Nan Jiang, Jing Zhang, Tina Morgan Ross, Xin‐Jie Chu, David Bartkovitz Hit paper breakdown →	2013	498
4	RG7204 (PLX4032), a Selective BRAFV600E Inhibitor, Displays Potent Antitumor Activity in Preclinical Melanoma Models Cancer Research ·Martina Hong Yang, Brian Higgins, Kenneth Daniel Kolinsky, Kathryn E. Packman, Zenaida Go, Raman Mahadevan Iyer, Stanley P. Kolis, Sylvia Zhao	2010	348
5	Discovery of RG7112: A Small-Molecule MDM2 Inhibitor in Clinical Development ACS Medicinal Chemistry Letters ·Binh Thanh Vu, Peter M. Wovkulich, Giacomo Pizzolato, Allen J. Lovey, Qingjie Ding, Nan Jiang, Jinjun Liu, Chunlin Zhao	2013	328
6	MDM2 Small-Molecule Antagonist RG7112 Activates p53 Signaling and Regresses Human Tumors in Preclinical Cancer Models Cancer Research ·Christian Tovar, Bradford J. Graves, Kathryn E. Packman, Zoran Filipovic, Brian Higgins Mingxuan Xia, Christine Tardell, Rosario Garrido, Edmund Lee	2013	249
7	Antitumor Activity of BRAF Inhibitor Vemurafenib in Preclinical Models of BRAF-Mutant Colorectal Cancer Cancer Research ·Martina Hong Yang, Brian Higgins, Kenneth Daniel Kolinsky, Kathryn E. Packman, William D. Bradley, Richard J. Lee, Kathleen J. Schostack, Mary Ellen Simcox	2011	196
8	Amivantamab (JNJ-61186372), an Fc Enhanced EGFR/cMet Bispecific Antibody, Induces Receptor Downmodulation and Antitumor Activity by Monocyte/Macrophage Trogocytosis Molecular Cancer Therapeutics ·Smruthi Vijayaraghavan, Lorraine Lipfert, Kristen M. Chevalier, Barbara S. Bushey, Ryan Lenhart, Jocelyn Andrel Sendecki, Marilda Beqiri, Hillary J. Millar	2020	185
9	Preclinical Profile of a Potent γ-Secretase Inhibitor Targeting Notch Signaling with In vivo Efficacy and Pharmacodynamic Properties Cancer Research ·Leopoldo L. Luistro, Wei He, Kathryn E. Packman, Maria Vilenchik, Daisy M. Carvajal, James J. Cai, Windy Berkofsky‐Fessler, Holly Hilton	2009	168
10	Resistance to Selective BRAF Inhibition Can Be Mediated by Modest Upstream Pathway Activation Cancer Research ·Fei Su, William D. Bradley, Qiongqing Wang, Martina Hong Yang, Lizhong Xu, Brian Higgins, Kenneth Daniel Kolinsky, Kathryn E. Packman	2011	150
11	A T-cell–redirecting bispecific G-protein–coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma Blood ·Kodandaram Pillarisetti, Suzanne C. Edavettal, Mark Mendonça, Yingzhe Li, Mark A. Tornetta, Alexander Babich, Nate Majewski, Matthew Husovsky	2020	144
12	Vitamin D3 receptor ablation alters mammary gland morphogenesis Development ·Glendon M. Zinser, Kathryn E. Packman, JoEllen Welsh	2002	135
13	Histone deacetylase inhibitors differentially stabilize acetylated p53 and induce cell cycle arrest or apoptosis in prostate cancer cells Cell Death and Differentiation ·Somdutta Roy, Kathryn E. Packman, Randy Jeffrey, Martin Tenniswood	2005	133
14	Mesenchymal Stem Cells in Early Entry of Breast Cancer into Bone Marrow PLoS ONE ·Kelly E. Corcoran, Katarzyna A. Trzaska, Helen Fernandes, Margarette Bryan, Marcelo Taborga, Venkatesh Srinivas, Kathryn E. Packman, Prem Shankar Patel	2008	126
15	The Combined Effect of FGFR Inhibition and PD-1 Blockade Promotes Tumor-Intrinsic Induction of Antitumor Immunity Cancer Immunology Research ·Sangeetha S. Palakurthi, Mari Kuraguchi, Sima J. Zacharek, Enrique Zudaire, Wei Huang, Dennis M. Bonal, Jeffrey Liu, Abha Dhaneshwar	2019	124
16	RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis Molecular Cancer Therapeutics ·Peter Brünker, Katharina Wartha, Thomas Friess, Sandra Grau-Richards, Inja Waldhauer, Claudia Ferrara, Meher Majety, Valeria Runza	2016	120
17	Teclistamab is an active T cell–redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma Blood Advances ·Kodandaram Pillarisetti, Gordon D. Powers, Leopoldo L. Luistro, Alexander Babich, Eric T. Baldwin, Xiaochun Zhang, Mark Mendonça, Nate Majewski	2020	114
18	Discovery of [4-Amino-2-(1-methanesulfonylpiperidin-4-ylamino)pyrimidin-5-yl](2,3-difluoro-6- methoxyphenyl)methanone (R547), A Potent and Selective Cyclin-Dependent Kinase Inhibitor with Significant in Vivo Antitumor Activity Journal of Medicinal Chemistry ·Xin‐Jie Chu, Wanda DePinto, David Bartkovitz, Sung‐Sau So, Binh Thanh Vu, Kathryn E. Packman, Christine Lukacs, Qingjie Ding	2006	102
19	Discovery of Sulanemadlin (ALRN-6924), the First Cell-Permeating, Stabilized α-Helical Peptide in Clinical Development Journal of Medicinal Chemistry ·Vincent Guerlavais, Tomi K. Sawyer, Luis A. Carvajal, Yong Seok Chang, Bradford J. Graves, Jian-Guo Ren, Karen A. Olson, Kathryn E. Packman	2023	102
20	In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials Molecular Cancer Therapeutics ·Wanda DePinto, Xin‐Jie Chu, Xuefeng Yin, Kathryn E. Packman, Petra Goelzer, Allen J. Lovey, Yingsi Chen, Hong Qian	2006	95

About Kathryn E. Packman

Kathryn E. Packman is a scholar working on Oncology, Hematology, Molecular Biology, Radiology, Nuclear Medicine and Imaging and Pathology and Forensic Medicine, having authored 62 papers that have together received 5.5k indexed citations. Recurring topics across this work include Cancer-related Molecular Pathways (13 papers), Melanoma and MAPK Pathways (9 papers), Monoclonal and Polyclonal Antibodies Research (6 papers), Acute Myeloid Leukemia Research (5 papers), Cancer Immunotherapy and Biomarkers (4 papers), Prostate Cancer Treatment and Research (4 papers), Chemical Synthesis and Analysis (4 papers) and Angiogenesis and VEGF in Cancer (4 papers). The work is most often cited by research in Oncology (1.8k citations), Molecular Biology (2k citations), Hematology (360 citations), Genetics (157 citations) and Computational Theory and Mathematics (295 citations). Kathryn E. Packman has collaborated with scholars based in United States, Switzerland and Belgium. Frequent co-authors include Brian Higgins, Christian Tovar, Kenneth Daniel Kolinsky, David C. Heimbrook, Zoran Filipovic, Lyubomir T. Vassilev, Binh Thanh Vu, Bradford J. Graves, Kelli Glenn and Jinjun Liu. Their work appears in journals such as Molecular Cancer Therapeutics, Cancer Research, Blood, Journal of Medicinal Chemistry and ACS Medicinal Chemistry Letters.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Kathryn E. Packman

Impact in

Papers in i

In The Last Decade

Kathryn E. Packman

Kathryn E. Packman's Hit Papers

Peers

Countries citing papers authored by Kathryn E. Packman

Fields of papers citing papers by Kathryn E. Packman

All Works

About Kathryn E. Packman

Explore authors with similar magnitude of impact

Papers in